Flagship Ventures Fund IV General Partner
Latest statistics and disclosures from Flagship Ventures Fund IV General Partner's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MCRB, EDIT, Syros Pharmaceuticals, T2 Biosystems, Eleven Biotherapeutics, and represent 100.00% of Flagship Ventures Fund IV General Partner's stock portfolio.
- Added to shares of these 2 stocks: EDIT (+$121M), Syros Pharmaceuticals (+$87M).
- Started 2 new stock positions in Syros Pharmaceuticals, EDIT.
- Reduced shares in these 1 stock: MCRB (-$41M).
- Flagship Ventures Fund IV General Partner was a net buyer of stock by $168M.
- Flagship Ventures Fund IV General Partner has $585M in assets under management (AUM), dropping by 15.43%.
- Central Index Key (CIK): 0001508051
Portfolio Holdings for Flagship Ventures Fund IV General Partner
Flagship Ventures Fund IV General Partner holds 5 positions in its portfolio as reported in the June 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Seres Therapeutics (MCRB) | 63.0 | $368M | -9% | 13M | 29.05 |
|
| Editas Medicine (EDIT) | 20.7 | $121M | NEW | 5.0M | 24.40 |
|
| Syros Pharmaceuticals | 14.9 | $87M | NEW | 4.8M | 18.15 |
|
| T2 Biosystems | 1.0 | $5.9M | 742k | 7.89 |
|
|
| Eleven Biotherapeutics | 0.4 | $2.5M | 1.5M | 1.68 |
|
Past Filings by Flagship Ventures Fund IV General Partner
SEC 13F filings are viewable for Flagship Ventures Fund IV General Partner going back to 2015
- Flagship Ventures Fund IV General Partner 2016 Q2 filed Aug. 15, 2016
- Flagship Ventures Fund IV General Partner 2015 Q4 filed Feb. 12, 2016